Evidence map›Paper›PMID 32671519›Full record

SynthesisCurrent atherosclerosis reports2020

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis.

Marco Lombardi, Juan G Chiabrando, Giovanni M Vescovo, Edoardo Bressi, Marco Giuseppe Del Buono, Salvatore Carbone, Rachel A Koenig, Benjamin W Van Tassell, Antonio Abbate, Giuseppe Biondi-Zoccai and 1 more

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Marco LombardiVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Juan G ChiabrandoInterventional Cardiology Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Giovanni M VescovoDepartment of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Edoardo BressiVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Marco Giuseppe Del BuonoVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Salvatore CarboneVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Rachel A KoenigTompkins-McCaw Library for the Health Sciences, VCU Libraries Virginia Commonwealth University, Richmond, VA, USA.
Benjamin W Van TassellVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Antonio AbbateVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Giuseppe Biondi-ZoccaiDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Dave L DixonVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. dldixon@vcu.edu.ORCID 0000-0001-7560-9521
Virginia Commonwealth University · USUniversità Cattolica del Sacro Cuore · ITClinica Mediterranea · ITUniversidad de Buenos Aires · ARUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewOmega-3 fatty acid (O3FA) supplementation has shown conflicting evidence regarding its benefit in cardiovascular events. We performed a pairwise and network meta-analysis to elucidate the benefit of different doses of O3FA supplementation in cardiovascular prevention. RECENT

findingsFourteen studies were identified providing data on 125,763 patients. A prespecified cut-off value of < 1 g per day was set for low-dose (LD) O3FA and > 1 g per day for high-dose (HD) O3FA. The efficacy outcomes of interest were total death, cardiac death, sudden cardiac death, myocardial infarction, stroke, coronary revascularization, unstable angina, and major vascular events. Safety outcomes of interest were bleeding, gastrointestinal disturbances, and atrial fibrillation events. HD treatment was associated with a lower risk of cardiac death (IRR 0.79, 95% CI [0.65-0.96], p = 0.03 versus control), myocardial infarction (0.71 [0.62-0.82], p < 0.0001 versus control and 0.79 [0.67-0.92], p = 0.003 versus LD), coronary revascularization (0.74 [0.66-0.83], p < 0.0001 versus control and 0.74 [0.66-0.84], p < 0.0001 versus LD), unstable angina (0.73 [0.62-0.86], p = 0.0001 versus control and 0.74 [0.62-0.89], p = 0.002 versus LD), and major vascular events (0.78 [0.71-0.85], p < 0.0001 versus control and 0.79 [0.72-0.88], p < 0.0001 versus LD). HD treatment was associated with increased risk for bleeding events (1.49 [1.2-1.84], p = 0.0002 versus control and 1.63 [1.16-2.3], p = 0.005 versus LD) and increased atrial fibrillation events compared to control (1.35 [1.1-1.66], p = 0.004). HD O3FA treatment was associated with lower cardiovascular events compared to LD and to control, but increased risk for bleeding and atrial fibrillation events.

Indexed as

Dietary SupplementsAgedAtrial FibrillationDeath, Sudden, CardiacDose-Response Relationship, DrugFatty Acids, Omega-3FemaleHemorrhageHumansMaleMiddle AgedMyocardial InfarctionRiskStrokeTreatment OutcomeFatty Acids, Omega-3Cardiovascular eventsOmega 3 fatty acidsPreventionPUFA

Identifiers

PMID32671519
OpenAlexW3043699463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.